AN2・セラピューティクス
AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.29 | $0 | -$12M |
| 2025 Q4 | -0.29 | $0 | -$5M |
| 2025 Q3 | -0.31 | $0 | -$6M |
| 2025 Q2 | -0.21 | $0 | -$8M |
| 2025 Q1 | -0.35 | $0 | -$11M |
| 2024 Q4 | -0.25 | $0 | -$5M |
| 2024 Q3 |
| -0.43 |
| $0 |
| -$12M |
| 2024 Q2 | -0.48 | $0 | -$14M |